CS6005-R

CS6005-R is a next-generation small-molecule inhibitor of the RET (Rearranged during Transfection) tyrosine kinase, developed by CStone Pharmaceuticals. It is specifically designed to overcome resistance mechanisms that emerge following treatment with first-generation RET inhibitors, such as pralsetinib and selpercatinib. CS6005-R targets a broad spectrum of RET alterations, including wild-type RET, gatekeeper mutations (e.g., V804L/M), and solvent front mutations (e.g., G810R/S/C), which are common drivers in solid tumors like non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). The drug aims to provide a therapeutic option for patients who have progressed on initial RET-targeted therapies.